Abbott has received approval of the new antibody test against coronavirus.

image

Abbott has received approval of the new antibody test against coronavirus.

The new antibody test will first be used on Abbott's ARCHITECT® i1000SR and i2000SR laboratory devices, followed by the Alinity ™ i system. The test is ready for use in hospitals in Turkey.

Abbott has obtained the European Standards Compliance (CE) certificate under the EU's In Vitro Medical Diagnostic (IVD) Devices Regulation (98/79 / EC) for the laboratory-based serology blood test used to detect the IgG antibody indicating exposure to coronavirus (COVID-19). explained. Antibody testing is an important step in determining whether a person has been infected before. The antibody test, which provides information about how long the virus remains in the body and whether it has been immunized against the virus, provides a better understanding of the virus. This information can also help support treatment and vaccine development efforts.

Abbott's new antibody test will be held on May 15, 2020 by T.C. Ministry of Health General Directorate of Public Health and approved by Turkey Pharmaceuticals and Medical Devices Agency. Turkey made a statement on the Abbott Diagnostic Test Business Unit Director Fuat Bescel of the Covidien-19 test may help fight the pandemic Abbott said he focused on riding as fast as possible to the market. Besceli said, “We are proud to present our antibody tests that can detect over 99 percent of who is infected with the virus. These tests will be useful in the stage of returning to normal life ”.

Thanks to antibody tests, more people can be tested

Technically, molecular diagnostic tests are used to detect an existing infection, while antibody tests show whether a person has previously been infected. Abbott's SARS-CoV-2 IgG test detects the IgG protein that the body produces in the final stages of the infection and can remain in the body for months, maybe years, after the person heals. The test gives accurate results with a specificity and sensitivity of over 99 percent in people 14 days and after the onset of symptoms.

Abbott's IgG antibody test will initially be used on ARCHITECT® i1000SR and i2000SR laboratory devices.